Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:IDRA
Date1/2000
Raised
Post IPO Valuation

General Information

Offices

Cambridge, USA
167 Sidney Street
Cambridge, MA, 02139
USA

People

Chief Executive Officer and President, Board of Directors
Chairman of the Board & Board of Directors
Vice President, Development Programs and Alliance Management
Vice President, Clinical Development
Board of Directors
Board of Directors
Board of Directors
Board of Directors
Show All People

Funding

TOTAL $53.8M
FUNDING TOTAL $13.8M
Venture Round, 1/2010
Merck KGaA
$4.3M
Venture Round, 11/2011
$9.5M
POST IPO FUNDING TOTAL $40M
Post IPO Equity, 2/2014
$40M

Tags

Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Recent Milestones

Videos

Screenshots

Idera Pharmaceuticals screenshot
Above: Home Page
Uploaded: 1/20/10

Stock Price

Sources

  1. Idera nets $4.3M milestone pay from Merck (masshightech.com) [edit]
  2. Idera raises $9.5M from stock offering (masshightech.com) [edit]
  3. Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants (businesswire.com) [edit]
  4. Idera to net $3.8M milestone pay from Merck (masshightech.com) [edit]
    Struggling Idera Pharmaceuticals raises $7M (masshightech.com) [edit]
Edit This Page
Last Edited 2/25/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy